Toll-like receptor antagonist compounds and methods of use

US11370794B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11370794-B2
Application numberUS-201716348816-A
CountryUS
Kind codeB2
Filing dateNov 9, 2017
Priority dateNov 11, 2016
Publication dateJun 28, 2022
Grant dateJun 28, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to compounds of formula (I):or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of formula (I): or a salt or solvate thereof, wherein: A 1 is C or N; A 2 is CR 2 , N, or NR 2a ; A 3 is CR 30 , N, or NR 3a ; A 4 is N or CR 4 ; A 5 is N or CR 5 ; provided that two, three or four of A 1 , A 2 , A 3 , A 4 , and A 5 are N; wherein the dashed lines indicate partial or delocalized bonds in an aromatic ring; i and j are independently 0, 1, or 2; R 1 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, or 3-12-membered heterocyclyl; wherein the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclyl are independently optionally substituted by R 10A ; each R 2 , R 3 , R 30 , R 4 , and R 5 is independently hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, or 3-12-membered heterocyclyl; wherein the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclyl are independently optionally substituted by R 10A ; each R 2a and R 3a is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, or 3-12-membered heterocyclyl; wherein the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclyl are independently optionally substituted by R 10A ; each R 6 , where present, is independently C 1 -C 6 alkyl optionally substituted by R 10A ; n is 0, 1, 2, 3, or 4; U is a bond or methylene optionally substituted by R 10 ; V is a bond or C 1 -C 2 alkylene optionally substituted by R 10 ; W is a bond or C 1 -C 4 alkylene optionally substituted by one or both of R W1 and R W2 ; X is CR X1 R X2 —; Y is CR Y1 R Y2 —; R 7 is hydrogen, C 1 -C 6 alkyl, or taken together with R 8 to form an ethylene optionally substituted by R 10 , or taken together with R Y1 , R X1 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 ; R 8 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10 , C 6 -C 14 aryl, 5-10-membered heteroaryl, or taken together with R 7 to form an ethylene optionally substituted by R 10 , or taken together with R Y1 , R Y2 , R X1 , R X2 or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R 10 , where present, to form a C 1 -C 6 alkylene, or taken together with R 9 and the nitrogen atom to which they are attached to form a 3-12-membered heterocyclyl optionally substituted by 10° or a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R Y1 , R Y2 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y1 , R Y2 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y2 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ; R 9 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10 , or taken together with R 8 and the nitrogen atom to which they are attached to form a 3-12-membered heterocyclyl optionally substituted by R 10 or a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R Y1 , R Y2 , R 8 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y1 , R Y2 , R 8 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y1 , R Y2 , R 8 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ; R W1 , where present, is C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R 7 , R 8 , R X1 , or R Y1 to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R W2 , R X1 , R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ; R W2 , where present, is C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R W1 , R X1 ; R X2 ; R Y1 ; R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ; R X1 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R 7 , R 8 , R Y1 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ; R X2 is hydrogen or C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R X1 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R 8 to form a C 1 -C 6 alkylene optionally substituted by R 10 ; R Y1 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R 7 , R 8 , R X1 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 ; R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ; R Y2 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R Y1 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y1 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y1 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R 8 to form a C 1 -C 6 alkylene optionally substituted by R 10 ; each R 10 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3-12-membered heterocyclyl, 5-10-membered heteroaryl, C 6 -C 14 aryl, halogen, —CN, —OR 11 , —SR 11 , —NR 12 R 13 , —NO 2 , —C═NH(OR 11 ), —C(O)R 11 , —OC(O)R 11 , —C(O)OR 11 , —C(O)NR 12 R 13 , —NR 11 C(O)R 12 , —NR 11 C(O)OR 12 , —NR 11 C(O)NR 12 R 13 , —S(O)R 11 , —S(O) 2 R 11 , —NR 11 S(O)R 12 , —NR 11 S(O) 2 R 12 , —S(O)NR 12 R 13 , —S(O) 2 NR 12 R 13 , or —P(O)(OR 12 ) (OR 13 ); wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3-12-membered heterocyclyl, 5-10-membered heteroaryl and C 6 -C 14 aryl of R 10 are independently optionally substituted by halogen, —CN, oxo, —OR 14 , —SR 14 , —NR 14 R 15 , —C(O)R 14 , —C(O)OR 14 , —S(O)R 14 , —S(O) 2 R 14 , —P(O)(OR 14 )(OR 15 ), 3-12

Assignees

Inventors

Classifications

  • Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

  • C07D487/04Primary

    Ortho-condensed systems · CPC title

  • Benzopyrazoles; Hydrogenated benzopyrazoles · CPC title

  • with aryl radicals directly attached in position 2 · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11370794B2 cover?
The invention relates to compounds of formula (I):or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with …
Who is the assignee on this patent?
Dynavax Tech Corp
What technology area does this patent fall under?
Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).